 Immune effector cell therapy is emerging as a promising approach in the field of cancer immunotherapy . Clinical IEC trials predominantly using chimeric antigen receptor T cells have shown excellent responses in CD19

@highlight Chimeric antigen receptor T therapy for solid tumors has encountered challenges in early clinical trials.
@highlight Toxicity antigen targeting trafficking and immune evasion hamper cell activity.
@highlight Novel techniques are being explored to improve treatment safety and efficacy.
